AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of the claims:

- 1. (Cancelled)
- 2. (Currently amended): A method for enhancing the function of normal or abnormal damaged excitable tissue in a mammal, comprising administering peripherally to said a mammal in need thereof a peripherally effective, non-toxic, excitable tissue enhancing amount of recombinant EPO, wherein said enhancing the function of excitable tissue results in the enhancement of associative learning or memory.
- 3. (Currently amended): A method for enhancing the function of normal or abnormal damaged excitable tissue in a mammal, comprising administering peripherally to said a mammal in need thereof a peripherally effective, non-toxic, excitable tissue enhancing amount of recombinant EPO, The method of Claim 1 wherein said enhancing the function of excitable tissue is used in the treatment of cognitive dysfunction.
- 4. (Currently amended): A method for enhancing the function of normal or abnormal damaged excitable tissue in a mammal, comprising administering peripherally to said a mammal in need thereof a peripherally effective, non-toxic, excitable tissue enhancing amount of recombinant EPO, wherein said excitable tissue is central nervous system tissue or peripheral nervous system tissue.
- 5. (Currently amended): A method for enhancing the function of normal or abnormal damaged excitable tissue in a mammal, comprising administering peripherally to said a mammal in need thereof a peripherally effective, non-toxic, excitable tissue enhancing amount of recombinant EPO, wherein said administration comprises oral, topical, intraluminal or by inhalation or parenteral administration.
- 6. (Original): The method of Claim 5 wherein said parenteral administration is intravenous.
- 7. (Currently amended): A method for enhancing the function of normal or abnormal damaged excitable tissue in a mammal, comprising administering peripherally to said a

mammal <u>in need thereof</u> a peripherally effective, non-toxic, excitable tissue enhancing amount of recombinant EPO, wherein said administration is acute or chronic.

- 8. (Cancelled)
- 9. (Currently amended): A method for enhancing the function of normal or abnormal damaged excitable tissue in a mammal, comprising administering peripherally to said a mammal in need thereof comprising administering peripherally to said mammal a peripherally effective, non-toxic, excitable tissue enhancing amount of recombinant EPO, wherein said EPO is administered at a dose greater than the dose necessary to maximally stimulate erythropoiesis.
 - 10. (Cancelled)
 - 11. (Cancelled)